MBX Biosciences (MBX) insider buying

Healthcare · Biotechnology · Market cap $2.2B

4 open-market purchases of MBX by MBX Biosciences's executives and directors since September 2025, worth $13M in total, from SEC Form 4 filings.

The most recent: P. Kent Hawryluk bought $525,585 on March 13, 2026.

The biggest buyer over the period is Patrick J Heron: 1 purchase, $12M.

By year

YearPurchasesValue
20261$525,585
20253$13M

Biggest buyers

InsiderBuysValue
Patrick J Heron
1$12M
P. Kent Hawryluk
2$798,385
Steven L Hoerter
1$265,000

Every purchase

Newest first. From SEC Form 4 filings. Insider buying across the market.

DateInsiderSharesPriceValueFiling
Mar 13, 2026 P. Kent Hawryluk
 18,500$28.41$525,585 Form 4
Oct 20, 2025 P. Kent Hawryluk
 20,000$13.64$272,800 Form 4
Oct 17, 2025 Steven L Hoerter
 20,000$13.25$265,000 Form 4
Sep 26, 2025 Patrick J Heron
 666,666$18.00$12M Form 4
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for MBX.
Open MBX in Investingly

Questions

Are MBX Biosciences insiders buying the stock?

4 open-market purchases of MBX by MBX Biosciences's executives and directors since September 2025, worth $13M in total, from SEC Form 4 filings. The most recent: P. Kent Hawryluk bought $525,585 on March 13, 2026.

What counts as insider buying here?

Open-market purchases (Form 4 code P) by officers and directors. Option exercises, grants and purchases by 10% owners are left out.

From MBX Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.